Payment overview · 2025
General Payments
$2,083.87
116 reported records · 18 companies
Healthcare provider profile · identity verified
Vikas Passi, MD
Allopathic & Osteopathic Physicians|Family Medicine · WATSONTOWN, PA · NPI 1710932769
Verified facts
What the public records show
CMS Open Payments records show Vikas Passi, MD received $2,083.87 in general payments during 2025 across 116 reported records.
Novo Nordisk Inc accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Paxlovid, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1023 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1023 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $503.12 | 24.1% | 30 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $320.47 | 15.4% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $291.94 | 14.0% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $167.26 | 8.0% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $153.70 | 7.4% | 10 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.38 | 7.2% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $142.84 | 6.8% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $65.06 | 3.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.09 | 2.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.98 | 2.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.57 | 2.0% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.00 | 1.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.41 | 1.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.87 | 0.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.79 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.56 | 0.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $14.93 | 0.7% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $12.90 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,083.87 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $420.66 | 24 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $206.47 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $190.60 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $182.02 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $149.38 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $144.01 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $137.21 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $134.62 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $119.85 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.00 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $97.87 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $92.25 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $82.46 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $65.06 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $55.83 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.83 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $51.76 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $49.77 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.98 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.57 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $33.41 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $12.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1023 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 209 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 160 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 20 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 21 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1023 | 128 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
209 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1023 | 128 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1518 | 317 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1086 | 182 |
| Eliquis | Apixaban | 1023 | 128 |
| Furosemide | Furosemide | 917 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 865 | 184 |
| Metoprolol Succinate | Metoprolol Succinate | 715 | 157 |
| Sertraline Hcl | Sertraline Hcl | 631 | 120 |
| Gabapentin | Gabapentin | 599 | 119 |
| Potassium Chloride | Potassium Chloride | 575 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 559 | 134 |
| Tamsulosin Hcl | Tamsulosin Hcl | 484 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 461 | 136 |
| Omeprazole | Omeprazole | 446 | 107 |
| Prednisone | Prednisone | 445 | 218 |
| Lisinopril | Lisinopril | 426 | 98 |
| Quetiapine Fumarate | Quetiapine Fumarate | 426 | 56 |
| Donepezil Hcl | Donepezil Hcl | 414 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 405 | 75 |
| Mirtazapine | Mirtazapine | 395 | 63 |
| Metformin Hcl | Metformin Hcl | 393 | 97 |
| Losartan Potassium | Losartan Potassium | 359 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 358 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 335 | 58 |
| Trazodone Hcl | Trazodone Hcl | 324 | 66 |
| Warfarin Sodium | Warfarin Sodium | 321 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 320 | 69 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 298 | 85 |
| Famotidine | Famotidine | 282 | 86 |
| Simvastatin | Simvastatin | 280 | 45 |
| Myrbetriq | Mirabegron | 267 | 31 |
| Levetiracetam | Levetiracetam | 261 | 25 |
| Xarelto | Rivaroxaban | 261 | 27 |
| Ezetimibe | Ezetimibe | 258 | 89 |
| Montelukast Sodium | Montelukast Sodium | 258 | 67 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 242 | 44 |
| Allopurinol | Allopurinol | 221 | 47 |
| Memantine Hcl | Memantine Hcl | 220 | 31 |
| Jardiance | Empagliflozin | 209 | 57 |
| Finasteride | Finasteride | 205 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 183 | 35 |
| Torsemide | Torsemide | 175 | 36 |
| Buspirone Hcl | Buspirone Hcl | 170 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 40 |
| Ozempic | Semaglutide | 160 | 45 |
| Divalproex Sodium | Divalproex Sodium | 154 | 22 |
| Topiramate | Topiramate | 149 | 43 |
| Baclofen | Baclofen | 147 | 26 |
| Colestipol Hcl | Colestipol Hcl | 145 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 144 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 141 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 28 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 139 | 17 |
| Carvedilol | Carvedilol | 137 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 134 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 119 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 61 |
| Spironolactone | Spironolactone | 115 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 114 | 82 |
| Celecoxib | Celecoxib | 113 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 31 |
| Tramadol Hcl | Tramadol Hcl | 107 | 43 |
| Novolog Flexpen | Insulin Aspart | 105 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 101 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 100 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 98 | 40 |
| Sucralfate | Sucralfate | 98 | 22 |
| Risperidone | Risperidone | 96 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 93 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 27 |
| Atenolol | Atenolol | 85 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 15 |
| Olanzapine | Olanzapine | 81 | 11 |
| Pregabalin | Pregabalin | 81 | 20 |
| Trulicity | Dulaglutide | 81 | 17 |
| Alendronate Sodium | Alendronate Sodium | 79 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 79 | 12 |
| Latanoprost | Latanoprost | 79 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 16 |
| Tradjenta | Linagliptin | 77 | suppressed |
| Amoxicillin | Amoxicillin | 75 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 74 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 44 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 11 |
| Cefdinir | Cefdinir | 67 | 55 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 66 | 18 |
| Clindamycin Hcl | Clindamycin Hcl | 66 | 41 |
| Glipizide Er | Glipizide | 66 | 26 |
| Januvia | Sitagliptin Phosphate | 65 | 11 |
| Mupirocin | Mupirocin | 64 | 41 |
| Alprazolam | Alprazolam | 63 | 16 |
| Bumetanide | Bumetanide | 63 | suppressed |
| Meloxicam | Meloxicam | 60 | 17 |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Primidone | Primidone | 58 | 14 |
| Aripiprazole | Aripiprazole | 56 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 55 | 15 |
| Mometasone Furoate | Mometasone Furoate | 55 | 44 |
| Cefuroxime | Cefuroxime Axetil | 54 | 35 |
| Lorazepam | Lorazepam | 54 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 17 |
| Metformin Hcl Er | Metformin Hcl | 51 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 51 | suppressed |
| Lactulose | Lactulose | 50 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 13 |
| Cephalexin | Cephalexin | 49 | 36 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 47 | 13 |
| Levemir Flexpen | Insulin Detemir | 47 | suppressed |
| Nystatin | Nystatin | 47 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 32 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 35 |
| Fluconazole | Fluconazole | 44 | 32 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 12 |
| Ketoconazole | Ketoconazole | 44 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 24 |
| Nitroglycerin | Nitroglycerin | 43 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 26 |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Amantadine | Amantadine Hcl | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 38 | 14 |
| Levofloxacin | Levofloxacin | 38 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 38 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 38 | 21 |
| Dutasteride | Dutasteride | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 36 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 21 |
| Glipizide | Glipizide | 32 | suppressed |
| Novolog | Insulin Aspart | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 13 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Budesonide | Budesonide | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | 13 |
| Ondansetron Odt | Ondansetron | 28 | 21 |
| Valacyclovir | Valacyclovir Hcl | 28 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Mirabegron Er | Mirabegron | 27 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 25 | suppressed |
| Lamotrigine Er | Lamotrigine | 25 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Water | Water For Irrigation,sterile | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | 18 |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 14 |
| Fentanyl | Fentanyl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Prolia | Denosumab | 21 | 18 |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Cyclosporine | Cyclosporine | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Ofloxacin | Ofloxacin | 19 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 14 |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Nystop | Nystatin | 18 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Actemra Actpen | Tocilizumab | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Leflunomide | Leflunomide | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Thiothixene | Thiothixene | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Epinastine Hcl | Epinastine Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Insulin Lispro Junior Kwikpen | Insulin Lispro | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 11 |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Sulindac | Sulindac | 12 | suppressed |
| Tobramycin | Tobramycin | 12 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,083.87 · 116 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, CAMZYOS, CAPLYTA, CAPVAXIVE, CeQur Simplicity, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, GEMTESA, Hillrom - Cardiac Ambulatory Monitor, JARDIANCE, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error